Takeda ( TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily ...
The nonprofit Association of Migraine Disorders is reshaping public understanding of migraine through its global Shades For Migraine campaign. Designed to smash ...
For millions of people, cannabis has become the unofficial prescription for lost sleep. But what feels like a solution may be ...
Kirstyn Hill has worked as a clinical pediatric and women’s health pharmacist since 2020. She was driven to work with a patient population that is not often able to easily speak up for themselves and ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Ayanna Redwood-Crawford Ayanna Redwood-Crawford is a writer covering beauty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results